Xenetic Biosciences Q3 2026 Results: Net Loss of $1.7M, Loss Widens
Xenetic Biosciences reported a net loss of $3.1 million for the nine months ended September 30, 2026, compared to $2.1 million in the prior year period, driven primarily by a significant increase in general and administrative expenses. Total revenue, derived from royalties, remained relatively flat at $2.2 million for the nine-month period. The company ended the quarter with $5.8 million in cash and is focused on advancing its systemic DNase program into clinical trials.
- Key figure
- Net loss $1.7M